Lead Plaintiff Deadline: May 13, 2019
Please Upload related files below
Fill in below.
Looking for more?
(1) Corbus improperly changed the primary efficacy endpoint for the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study results did not have statistical significance; and (3) as a result, Corbus’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
In order to be included in the lawsuit, you must have incurred a loss on shares of , either: A) purchased or acquired during the class period listed above, if applicable; or B) pursuant to the Initial Public Offering (IPO) of , if applicable.
If you suffered a loss in during the relevant time frame, or pursuant to ’s IPO if listed above, you have until May 13, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.